This systematic review and meta-analysis (2024) examined the side effects of MDMA-assisted psychotherapy (MDMA-AP) across Phase II and III studies. Thirteen studies were included, with most showing an increase in side effects during medication sessions and the following week compared to control conditions. Despite these findings, the overall certainty of evidence was rated as very low to moderate, and the quality of side effects reporting was generally poor, suggesting further research is needed to fully understand the safety profile of MDMA-AP.
Evidence suggests that MDMA-assisted psychotherapy (MDMA-AP) has therapeutic potential for treatment of psychiatric illness. We conducted the first comprehensive systematic review and meta-analysis of the side effects of MDMA-AP across indications. We also assessed the quality of side effects-reporting in published trials of MDMA-AP. PubMed, EMBASE, PsycINFO, MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) were systematically searched. Phase 2 and 3 MDMA-AP studies were included; Phase 1 studies, which assessed MDMA without psychotherapy, were not. Quality of side effects-reporting was assessed against the CONSORT Harms 2022 guidelines. We also compared numbers of adverse events reported in publications to those recorded in ClinicalTrial.gov registers. Thirteen studies were included, with eight contributing to the meta-analysis. In Phase 2 studies, MDMA-AP was associated with increased odds of any side effect during medication sessions (OR = 1.67, 95%CI (1.12, 2.49)) and in the 7 days following (OR = 1.59, 95%CI (1.12, 2.24)) relative to control conditions. In Phase 3 studies, MDMA-AP was associated with increased odds of any adverse event during the treatment period relative to placebo-assisted psychotherapy (OR = 3.51, 95%CI (2.76, 4.46)). The majority of RCTs were rated as having high risk of bias. Certainty of the evidence was rated as very low to moderate according to the GRADE framework. No included RCT had adequate adherence to the CONSORT Harms 2022 recommendations and reporting rates were also low. Compared to placebo, MDMA-AP was associated with increased odds of side effects, which were largely transient and mild or moderate in severity. However, identified limitations in existing evidence indicate that further investigation is needed to better characterize the safety profile of MDMA-AP and guide implementation.
Papers cited by this study that are also in Blossom
Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)
Mitchell, J., Ot’alora G, M., van der Kolk, B. et al. · Nature Medicine (2023)
Sessa, B., Higbed, L., Durant, C. et al. · Journal of Psychopharmacology (2021)
Danforth, A. L., Grob, C. S., Struble, C. et al. · Psychopharmacology (2018)
Colcott and colleagues place MDMA-assisted psychotherapy (MDMA-AP) in the context of a rapidly advancing clinical literature, noting that the intervention combines pharmacotherapy and psychotherapy in protocols that typically include preparatory sessions, two to three full-day MDMA- or placebo-assisted sessions, and subsequent integration sessions. Earlier trials and reviews have suggested therapeutic potential for post‑traumatic stress disorder (PTSD) and possibly other conditions, and recent regulatory moves (for example, a TGA decision in Australia and an anticipated FDA approval) have increased interest in wider clinical use. At the same time, the authors highlight concerns about potential harms unique to combining a psychoactive drug with psychotherapy and about inconsistent or inadequate adverse-event assessment and reporting in existing trials. This paper therefore aimed to provide the first comprehensive, across‑indications systematic review and meta-analysis of side effects in Phase II and III trials of MDMA-AP. In addition to estimating pooled risks for a range of safety outcomes, the investigators assessed the quality of harms reporting in published randomized controlled trials against the CONSORT Harms 2022 guideline and compared adverse events reported in publications with those recorded on ClinicalTrials.gov. The term "side effects" is used broadly to encompass spontaneous reactions, treatment‑emergent adverse events (TEAEs) and other harms as reported in the source trials.
The review was pre-registered on PROSPERO and conducted according to PRISMA. The authors searched PubMed, EMBASE, PsycINFO, MEDLINE and CENTRAL from inception to 30 October 2023 using terms combining MDMA, psychotherapy and safety-related keywords. Titles and abstracts were screened by a primary reviewer and full texts were independently reviewed by two authors, with disagreements resolved by consensus. Screening and data management used Covidence. Eligibility criteria limited inclusion to English-language, peer‑reviewed human studies that administered MDMA together with psychotherapy to treat a psychiatric condition; Phase I studies without psychotherapy were excluded, so only Phase II and Phase III trials were eligible. The primary reviewer extracted data which were checked by a second reviewer; authors were contacted for missing information and unresolvable missing items were coded as "Not Reported". For synthesis, the investigators conducted a narrative summary and performed pairwise meta-analyses when at least two studies contributed data to an outcome. Dichotomous outcomes were pooled as odds ratios (ORs) with 95% confidence intervals using the Mantel–Haenszel method and random-effects models to account for heterogeneity; I2 was used to quantify heterogeneity. Phase II and Phase III studies were analysed separately because of differences in how side effects were collected and reported. Subgroup analyses compared PTSD and non‑PTSD studies where possible, and sensitivity analyses examined effects of the method used to assess side effects and the number of medication sessions. Publication bias was not formally assessed when ≤10 studies contributed to an analysis. Primary outcomes were predefined separately for Phase II and Phase III. For Phase II the outcomes included: any side effect during medication sessions; any side effect within 7 days after sessions; TEAEs; and psychiatric TEAEs. Phase II "side effects" often came from a spontaneously reported reactions list (expected reactions from healthy‑volunteer studies), while TEAEs were events not on that list or lasting >7 days. For Phase III primary outcomes were TEAEs across the treatment period and adverse events of special interest (AESIs) prespecified by the FDA (cardiac function, suicidality, and MDMA abuse/misuse/diversion). Study withdrawal was a primary outcome across all studies; secondary outcomes disaggregated event types (for example, anxiety) and reasons for withdrawal. Quality and bias assessments focused on harms reporting and side-effect outcomes. Two reviewers independently scored RCTs against the 17‑item CONSORT Harms 2022 checklist (1 = adequately reported; 0 = not/inadequately reported), with adherence ≥70% defined as adequate. Risk of bias for side-effect outcomes used the Cochrane RoB 2 tool, with Cohen's kappa calculated for inter‑rater agreement. The GRADE framework was applied to rate certainty of evidence for each outcome. Finally, adverse-event counts from publications were compared with entries on ClinicalTrials.gov where registry data were available.
Study selection yielded 13 eligible studies involving 333 unique participants; eight randomized controlled trials (RCTs) with 298 participants contributed to meta-analyses. Across the 13 studies the authors extracted 138 different safety outcomes, of which 64 had sufficient data for pooling. Measurement approaches were heterogeneous: most studies (11 of 13) used passive monitoring or spontaneous reporting, one used the UKU side‑effect scale, and a minority systematically assessed long‑term harms or specific domains such as suicidality (Columbia Suicide Severity Rating Scale used in eight studies) or cognitive function. Phase II and Phase III trials differed in how they collected and reported side effects, with Phase II studies separating "spontaneously reported reactions" and TEAEs, whereas Phase III studies reported TEAEs across the treatment period and additionally monitored AESIs. Phase II meta-analyses. Using spontaneously reported reactions as the outcome, MDMA-AP was associated with greater odds of any side effect during medication sessions (45% of MDMA participants vs 30% of controls; pooled OR = 1.67, 95% CI 1.12–2.49) and greater odds of any side effect in the 7 days following sessions (46% vs 31%; pooled OR = 1.59, 95% CI 1.12–2.24). Specific side effects with higher odds under MDMA-AP during medication sessions included anxiety and jaw clenching, with dose-dependent signals for jaw clenching (more likely at 125–150 mg). For PTSD-only Phase II analyses anxiety was more common in MDMA-AP participants during sessions and in the week after. In contrast, there was no difference between groups in the odds of experiencing any TEAE, psychiatric TEAE, or in rates of study withdrawal in Phase II analyses; PTSD subgroup analyses for TEAEs suggested lower odds under MDMA-AP in one analysis, but that comparison involved only two studies that used an active low‑dose control rather than inert placebo. Phase III meta-analyses. Pooled Phase III results indicated higher odds of any TEAE in MDMA-AP versus control (16% vs 5% reporting TEAEs; pooled OR = 3.51, 95% CI 2.76–4.46). Thirteen specific TEAEs reached statistical significance: muscle tightness; decreased appetite; nausea; excessive perspiration; feeling cold; restlessness; dilated pupils; jaw clenching/tight jaw; uncontrolled eye movements; feeling jittery; non‑cardiac chest pain/discomfort; blurred vision; and chills. No differences were detected for AESIs related to suicidality or cardiac function, and no AESIs related to abuse, misuse or diversion were reported. Both Phase III trials were PTSD studies, so subgroup analyses were not conducted. Across all studies there was no difference in odds of study withdrawal for any reason between MDMA-AP and control, and sensitivity analyses (method of side-effect assessment, number of medication sessions) did not materially change results. Risk of bias and reporting quality. With side effects specified as the outcome, seven of eight RCTs included in the meta-analyses were rated at high risk of bias and one had some concerns; Domain 4 (bias in measurement of the outcome) was the domain most frequently rated high risk. Inter‑rater agreement for overall bias was excellent (Cohen's kappa = 1.00). Under GRADE, all primary Phase II outcomes were rated as very low certainty; Phase III primary outcomes were rated low to moderate certainty, and withdrawal for any reason was rated as moderate certainty. Adherence to harms reporting and registry comparisons. No RCT achieved adequate adherence to the CONSORT Harms 2022 checklist (≥70%); median adherence was 50% (range 21–64%). Comparison with ClinicalTrials.gov data—possible for a subset of studies—revealed substantial under-reporting in publications: registries listed 1,487 non‑serious adverse events versus 661 reported in published articles, and 13 serious adverse events versus 9 published. Four serious adverse events reported on ClinicalTrials.gov but not in publications involved participants in MDMA-AP groups and comprised metastases to the central nervous system, a clavicle fracture, syncope, and suicidal behaviour.
Colcott and colleagues interpret the pooled findings as indicating that MDMA-AP increases the likelihood of experiencing side effects compared with placebo-AP, but that these effects are largely transient and of mild to moderate severity. In Phase II studies the increased odds were observed for spontaneously reported, expected reactions during and within 7 days of medication sessions, notably anxiety and jaw clenching; there were no differences in TEAEs or withdrawal, suggesting most short‑term events resolved quickly. Phase III trials showed larger and more numerous TEAE signals—likely reflecting greater statistical power in the larger sample—with increased odds for a range of acute effects consistent with known MDMA pharmacology. The authors emphasise several important caveats. First, the overall certainty of evidence was low for many outcomes, constrained by high risk of bias across most RCTs, heterogeneity in definitions and measurement of side effects, and limited sample representativeness. Second, harms reporting was often inadequate: none of the RCTs met CONSORT Harms 2022 adherence thresholds, and published articles omitted many adverse events that appeared in trial registries. Third, most studies relied on passive spontaneous reporting rather than systematic checklists, which can underestimate event rates. Fourth, insufficient data precluded robust assessment of longer‑term risks, dose–response relationships, or the extent to which expectations (for example, nocebo or blinding failure) influence reported harms. The authors therefore caution that current trial data do not permit high‑confidence conclusions about the full safety profile or risk–benefit ratio of MDMA-AP, particularly as implementation moves beyond highly selected trial populations. On the basis of these conclusions, the investigators call for improved harms assessment and transparent reporting in future trials, larger and more representative independent studies, systematic long‑term follow-up, routine use of standardised side‑effect checklists alongside spontaneous reporting, and post‑marketing surveillance in jurisdictions implementing MDMA-AP.
The authors conclude that, based on existing Phase II and Phase III trials, MDMA-AP is associated with a higher likelihood of mild to moderate transient side effects compared with placebo‑assisted psychotherapy, but that the evidence base has important limitations. They recommend improved and standardised assessment and reporting of harms (including adherence to CONSORT Harms 2022), larger independent trials with broader populations, explicit dose–response investigation, long‑term follow‑up, and systematic post‑marketing surveillance to better characterise safety as MDMA-AP is implemented in clinical settings.
In the past decade, research on the therapeutic use of 3,4methylenedioxymethamphetamine (MDMA) in psychotherapy has gathered pace. MDMA-assisted psychotherapy (MDMA-AP) uses a combined pharmacotherapy-psychotherapy model, with MDMA thought to 'catalyze' the effects of psychotherapy. In typical protocols, patients attend 3-4 initial 'preparatory' psychotherapy sessions, followed by 2-3 full day MDMA-(or placebo-) assisted sessions, each followed by 3-4 'integration' psychotherapy sessions. Methodological questions notwithstanding, growing evidence now suggests that MDMA-AP has therapeutic potential for posttraumatic stress disorder (PTSD)and possibly other psychiatric conditions. Several clinical trials are planned or ongoing. After a recent decision by the Australian Therapeutic Goods Administration (TGA), psychiatrists who are authorized prescribers can now prescribe MDMA for PTSD, making Australia the first country to schedule MDMA for medicinal use. It also appears likely that MDMA-AP will be approved by the U.S. Food and Drug Administration (FDA) for PTSD in 2024, with the first new drug application submitted to the FDA in late 2023. While the literature to date has largely concluded that MDMAand MDMA-AP are safe and well tolerated, concerns exist about the unique potential for substances like MDMA-when combined with psychotherapy -to cause harm, as well as inadequacies in the assessment and reporting of adverse events in existing research. A comprehensive understanding of potential safety issues in MDMA-AP is needed to inform both ongoing research and translation to clinical practice. While acute adverse effects of MDMA without psychotherapy have been determined in detail in placebo-controlled studies in healthy subjects, previous reviews of the safety and tolerability of MDMA-AP did not include meta-analyses of safety outcomes, or were limited to PTSD, terminal illness, or depression. Reviews which included meta-analyses of side effects did not assess the full range of safety outcomes reported, and no prior evidence synthesis has included the most recent Phase 3 study of MDMA-AP. Given regulatory changes to the status of MDMA-AP and the large pipeline of ongoing research, a comprehensive updated quantitative assessment of the safety and tolerability of MDMA-AP is timely. Here, we conducted a systematic review and meta-analysis of the side effects of MDMA-AP across psychiatric indications. We also addressed concerns about the adequacy of safety reporting in this research (e.g.,), providing the first assessment of the quality of side effect-reporting in published trials of MDMA-AP against the CONSORT Harms 2022 guidelines. Herein, 'side effects' is used as an umbrella term to describe the range of safety outcomes reported, which are variously described in published reports as spontaneously reported reactions, treatment emergent adverse events, adverse events, adverse effects and harms.
This systematic review and meta-analysis was pre-registered on PROSPERO (CRD42022355572) and is reported according to the PRISMA guidelines.
PubMed, EMBASE, PsycINFO, MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception using the following search terms: ("MDMA" OR "3,4-methylenedioxymethamphetamine") AND ("psychotherapy" OR "therapy") AND ("safe" OR "side" OR "adverse"), adapted to the technical requirements of each database (Table). No restriction on publication date or status was applied. The primary reviewer (JC) screened titles and abstracts. Full-text articles were reviewed by two independent authors (JC and AAG), with disagreements resolved by consensus. Searches were re-run just before the final analysis on 30 October 2023. Articles were screened and full-texts stored using Covidence (Veritas Health Innovation, Melbourne, Australia).
Studies included were published in English-language peer-reviewed journals and involved administration of one or more MDMA doses to humans (any dose frequency and timing) combined with psychotherapy, with the aim of treating a target psychiatric condition. Exclusion criteria included: (1) studies not including psychotherapy;papers not including original data e.g., reviews or commentaries; (3) conference abstracts; (4) book chapters; and (5) animal studies. These criteria meant that only Phase 2 and 3 studies were included: all Phase 1 studies assessed MDMA in the absence of psychotherapy.
We extracted information on:whether structured assessments were used to assess side effects or safety. Data were extracted by the primary reviewer (JC), and subsequently checked for accuracy and completeness by a second reviewer (AAG or SM). For missing data, reviewers first contacted study authors for unreported data and/or additional details. If additional information was not available, missing data were coded as "Not Reported".
Qualitative synthesis included the following steps: (1) data were extracted; (2) quality and risk of bias was assessed; and (3) findings were summarized in a table for each outcome. Results were synthesized using a narrative approach. Where at least two studies contributed data for an outcome, we conducted pairwise meta-analyses using Review Manager 5.4 (The Cochrane Collaboration, United Kingdom), comparing MDMA-AP to the control. Various doses for the MDMA group were pooled, and control groups included both active (low-dose MDMA) and inactive placebo. As outcomes were dichotomous, odds ratios (ORs) with 95% confidence intervals (95% CI) were calculated (Mantel-Haenzsel method). Random-effects models were used to control for heterogeneity. The significance level was set to p < 0.05 (two-tailed). Publication bias was not assessed as there were ≤10 studies in each analysis. Heterogeneity was estimated using the I² statistic, and subgroup analyses of PTSD studies and non-PTSD studies were completed (it was not possible to conduct more specific subgroup analyses as to particular types of PTSD patients-e.g., combat veteransas most studies included participants with a range of different types of trauma exposure). Sensitivity analyses were performed to assess effects of method used to assess side effects and number of medication sessions on the outcomes. We synthesized outcomes from Phase 2 and 3 studies separately due to differences in data collection and reporting. We defined the following primary outcomes for Phase 2 studies: (1) any side effect-during medication sessions; (2) any side effect-7 days following medication sessions; (3) treatment emergent adverse event (TEAE); and (4) psychiatric treatment emergent adverse event. Outcomes 1 and 2 were based on 'spontaneous reported reactions' data from Phase 2 studies, which included a subset of events that were judged to be expected based on evidence about MDMA's side effects from healthy control studies. TEAEs and psychiatric TEAEs were defined as events not on the expected reactions list, or which continued for >7 days after medication sessions. We defined the following primary outcomes for Phase 3 studies: (1) treatment emergent adverse event; and (2) adverse event of special interest. Consistent with Phase 3 studyreporting, we defined TEAEs for Phase 3 outcomes as any adverse event occurring across the treatment period. Adverse events of special interest were prespecified events related to cardiac function, suicidality, and MDMA abuse, misuse, or diversion identified as of special interest by the FDA. We also defined study withdrawal as a primary outcome across all studies. Secondary outcomes broke down each primary outcome by type (e.g., anxiety, reason for withdrawal; see Supplemental Tablefor primary and secondary outcomes).
Data on side effects from all included randomized controlled trials (RCTs) were independently assessed by two reviewers (JC and AAG) using the CONSORT Harms 2022 guideline, a 17-item checklist for reporting of harms in randomized trials. Each checklist item was scored individually (1 = adequately reported; 0 = inadequately or not reported at all) (e.g.,). Overall adherence to the CONSORT Harms guideline was calculated by dividing the sum of individual scores by the total number of items to generate a percentage. Adherence of ≥70% was defined as adequate. The 2007 FDA Amendments Act mandated the reporting of all clinical trial results, including adverse events, in the ClinicalTrials.gov database. To assess whether the adverse events reported in published articles aligned with those recorded in ClinicalTrial.gov, we compared the total number of serious and 'non-serious' adverse events from each of these sources for each trial.
The outcome being assessed for risk of bias was side effects. For the extracted RCTs, two reviewers (JC and AAG) independently assessed bias using the Cochrane Risk of Bias Tool for randomized trials (RoB 2), which evaluates bias arising from the randomization process, deviations from intended interventions, missing outcome data, outcome measurement and selection of the reported result. Cohen's kappa was calculated for overall bias to determine agreement between reviewers. Any conflict between reviewers was resolved through discussion to reach consensus. Further, based on the approach of the Cochrane Adverse Effects Methods Groupconsideration was given to the following issues that affect the quality of side effects-data: (1) how side effects data were collected (spontaneous reporting, use of structured scales or questionnaires); (2) how side effects were reported (systematically or ad hoc); and (3) the presence of a control group. The GRADE framework was used to assess the overall certainty of evidence for each outcome. Under the GRADE approach, RCT evidence is initially graded as high but then downgraded to lower levels depending on risk of bias, inconsistency, indirectness, imprecision and publication bias. Two reviewers (JC and AAG) completed this analysis, categorizing each outcome as having very low, low, moderate or high certainty.
Thirteen studies met inclusion criteria for the systematic review, involving 333 unique participants (Fig.). Characteristics of eligible studies are in Table. Five studies were excluded from meta-analyses because there was no control group (Table). The remaining eight RCTs included 298 participants, and reported 138 different safety outcomes, of which 64 provided sufficient data for meta-analysis (i.e., at least two studies per outcome; Table). A description of which studies contributed data to each analysis is provided in Table. Systematic review: measurement of side effects Of 13 studies included in the systematic review, most (n = 11) used passive monitoring of side effects. Onesystematically assessed side effects using the UKU Scale of Secondary Effects, while another formally assessed long-term follow-up outcomes, including harms, using a Long-Term Follow-Up Questionnaire. Use of scales to systematically assess specific side effects was mixed. Eight studies assessed suicidal ideation and behavior with the Columbia Suicide Severity Rating Scale. In addition, one studymeasured cognitive function using the Paced Auditory Serial Addition Task, Repeatable Battery for the Assessment of Neuropsychological Statusand Rey-Osterrieth Complex Figure, while anotherassessed dissociation using the Dissociative Experience Scale-II. Most studies measured vital signs at regular intervals during medication sessions. Four also assessed subjective units of distress (SUDs) during medication sessions. Systematic review: reporting of side effects Phase 2 and 3 studies used different methods to report side effects. Phase 2 studiestypically reported 'spontaneously reported reactions'a subset of adverse events that could be expected based on findings from healthy volunteer studiesduring and 7 days following medication sessions. These were collected and reported separately to TEAEs, defined as events not on the expected reactions list, or which continued for >7 days after medication sessions. In contrast, Phase 3 studiesdid not have separate data collection for spontaneously reported reactions and TEAEs, instead only reporting TEAEs across the entire treatment period. In addition, Phase 3 studies monitored and reported Adverse Events of Special Interest (AESI) relating to cardiac function, suicide risk and MDMA abuse, misuse or diversion. AESIs were prespecified based on FDA guidance. Only four studies reported sides effects by dose administered, while all other studies either combined doses in their analyses, or only use one dose.
We report on primary outcome measures below, together with any secondary outcomes achieving statistical significance (p < 0.05; Fig.). Sub-group analyses of PTSD studies are provided in Fig.. Other secondary outcomes are presented in Table.
Side effects-during medication sessions: In Phase 2 studies, the odds of experiencing any side effect during medication sessions were higher in the MDMA-AP group compared with controls. In total, 45% of MDMA-AP participants versus 30% of controls reported side effects during medication sessions. Odds of experiencing anxiety and jaw clenching during medication sessions were also higher in MDMA-AP than control participants. Based on dose-dependent reports, jaw clenching may be more likely to occur when receiving a higher dose (125 or 150 mg). All other specific side effects during medication sessions did not reach significance (Table). In PTSD studies only, anxiety was also more common under MDMA-AP than controls. All other results for PSTD studies did not reach significance. Side effects-7 days following medication sessions: In Phase 2 studies, the odds of experiencing any side effect in the 7 days following medication sessions were higher in the MDMA-AP group compared with controls. In total, 46% of MDMA-AP participants versus 31% of controls reported side effects in the 7 days following medication sessions. No specific side effects in the 7 days following medication sessions reached significance (Table). In PTSD studies only, the odds of experiencing any side effect in the 7 days following medication sessions were higher in the MDMA-AP group compared with controls, as were the odds of experiencing anxiety during this time. No other results for PSTD studies reached significance. Treatment emergent adverse events (TEAE): In Phase 2 studies, there was no difference in the odds of experiencing any TEAE in the MDMA-AP group compared with controls, and all specific TEAEs were also non-significant (Table). In PTSD studies only, the odds of experiencing any TEAE were lower in the MDMA-AP group compared with control. All other results for PSTD studies did not reach significance. There was no difference in the odds of experiencing any psychiatric TEAE in the MDMA-AP group compared with controls, and all specific psychiatric TEAEs were also non-significant (Table). The same results were observed in PSTD studies only.
Treatment emergent adverse events (TEAE): In Phase 3 studies, the odds of experiencing any TEAE in the MDMA-AP group compared with controls was higher, with 16% of MDMA-treated participants reporting TEAEs, compared with 5% of those treated with placebo. MDMA-AP was associated with increased odds of muscle tightness; decreased appetite; nausea; excessive perspiration; feeling cold; restlessness; dilated pupils; jaw clenching/tight jaw; uncontrolled eye movements; feeling jittery; non-cardiac chest pain/discomfort; blurred vision; and chills. All other specific TEAEs were non-significant (Table). Both Phase 3 studies focused on PSTD, so no sub-group analyses were performed. Adverse event of special interest (AESI): In Phase 3 studies, there was no difference in the odds of experiencing an AESI related to suicidality in the MDMA-AP group compared with controls, and all specific AESIs related to suicidality were also non-significant (Table). Similarly, there was no difference in the odds of experiencing an AESI related to cardiac function in the MDMA-AP group compared with controls, and all specific AESIs related to cardiac function were also non-significant (Table). No AESIs related to MDMA abuse, misuse or diversion were reported. As above, no sub-group analyses were performed.
Withdrawal: Across all studies, there was no difference in the odds of withdrawing from the study for any reason in the MDMA-AP group compared with controls, and all specific reasons for withdrawal were also non-significant (Table). In PTSD studies only, all results were also non-significant. Sensitivity analyses. Sensitivity analyses assessing effects of method used to assess side effects and number of medication sessions did not change outcomes.
With side effects specified as the outcome of interest, the risk of bias assessment found that of eight studies included in the Spontaneously reported reactions: subset of adverse events that could be expected based on findings from published studies in healthy volunteers. a Eight participants did not complete treatment, and six of the eight participants underwent at least one medication session prior to discontinuing study participation. meta-analysis, seven were rated as having a high risk of bias, and one was rated as having some concerns(see Fig.and Fig.). The Cohen's Kappa statistic for overall bias was 1.00 (i.e., excellent agreement between reviewers).
Tablepresents results of the GRADE assessment. For Phase 2 studies, all primary outcomes were rated as having very low certainty of evidence. For Phase 3 studies, two primary outcomes were rated as having low certainty of evidence, and one rated as moderate. For all studies, withdrawal for any reason was rated as having moderate certainty of evidence.
No included RCT had adequate adherence to the CONSORT Harms 2022 recommendations (>70%; Table). The median adherence rate was 50% (range 21-64%).
We were only able to complete this analysis for five studies for non-serious adverse events and eight for serious adverse events, because there were differences in how adverse events were reported between publications and ClinicalTrial.gov, and some studies did not have an entry or data on ClinicalTrial.gov (the two studies without ClinicalTrial.gov entries were also not registered on EudraCT). In ClinicalTrial.gov registers, we found 1487 nonserious adverse events recorded, versus 661 reported in published articles (Table). In ClinicalTrial.gov registers, we found 13 serious adverse events recorded, versus 9 reported in published articles (Table). The four serious adverse events not reported in published articles all concerned participants from MDMA-AP groups and included: (1) metastases to central nervous system; (2) clavicle fracture; (3) syncope; and (4) suicidal behavior.
To our knowledge, this is the first comprehensive systematic review and meta-analysis of side effects of MDMA-AP across psychiatric indications. In Phase 2 studies, although participants undergoing MDMA-AP had higher odds of experiencing side effects during and 7 days after medication sessions relative to placebo-AP participants, there was no difference in TEAEs. Moreover, the observed differences between active and placebo conditions were relatively modest. For Phase 3 studies, participants undergoing MDMA-AP had higher odds of experiencing any TEAE as well as thirteen different types of TEAEs compared with placebo. These were largely transient and mild to moderate in severity. These findings should, however, be interpreted with caution; we identified marked shortcomings in published Fig.Summary of meta-analysis results. Odds ratios (OR) and 95% confidence intervals (CIs) comparing MDMA-AP with control groups on all primary outcomes and secondary outcomes that achieved statistical significance (p < 0.05). OR > 1 indicates an increased likelihood of the event when treated with MDMA-AP compared with control groups and an OR < 1 indicates a reduced likelihood. Phase 2 studies: odds of experiencing any side effects during medication sessions was higher in the MDMA-AP group compared to control groups (p = 0.01), with anxiety and jaw-clenching more likely in the MDMA-AP group compared to control groups (ps < 0.05). Odds of experiencing any side effect in the 7 days following medication sessions were also higher in the MDMA-AP group compared to control groups (p = 0.007). Phase 3 studies: odds of experiencing any treatment emergent adverse events was higher in the MDMA-AP group compared to control groups (p < 0.001), with muscle tightness, decreased appetite, nausea, excessive perspiration, feeling cold, restlessness, dilated pupils, jaw clenching/tight jaw, uncontrolled eye movements, feeling jittery, non-cardiac chest pain/discomfort, blurred vision, and chills more likely in the MDMA-AP group compared to control groups (ps < 0.05). There were no other significant associations in Phase 2 or 3 studies. Fig.Quality assessment of studies included in the metaanalyses. Overall, seven of the eight studies included in the metaanalysis were rated as having a high risk of bias, with Domain 4 (bias in the measurement of the outcome) the domain most likely to be rated high risk across studies. information on side effects, including heterogeneity and weaknesses in how side effects were defined, assessed, and reported. Indeed, the certainty of evidence was rated as very low or low for 6 of 8 primary outcomes, with 2 rated as moderate certainty. This indicates that much remains unknown about the safety profile of MDMA-AP. In Phase 2 studies, MDMA-AP participants had 1.7 times greater odds of experiencing any side effect during medication sessions than placebo participants, and 1.6 greater odds of side effects in the 7 days following. These results, however, were based on 'spontaneously reported reactions' data, defined as a subset of adverse events that could be expected based on findings in healthy volunteers. It is therefore unsurprising that an effect was detected, albeit a small one. Participants treated with MDMA-AP also had 4.7 greater odds of anxiety and 4.8 greater odds of jaw clenching during medication sessions relative to placebo participants. Anxiety was also prominent in PTSD patients, who had 4.1 greater odds of anxiety during medication sessions when treated with MDMA-AP, and 4.8 greater odds in the 7 days following compared to the placebo-AP group. These findings are consistent with results of previous meta-analysesand evidence from healthy subjects. No differences between the MDMA-AP and control groups were observed in the odds of experiencing any TEAE, psychiatric TEAE or in withdrawal from the study, suggesting that side effects typically resolved within 7 days of MDMA-AP sessions and did not result in study withdrawal. Contrary to expectations, sub-group analyses found that people with PTSD who received MDMA-AP had 0.5 lower odds of experiencing any TEAE. Notably, only two studies were included in this meta-analysis, both of which used a low-dose MDMA active control rather than inert placebo. While active placebos improve blinding in studies evaluating MDMA-AP, this may complicate comparison of safety data between groups where treatments are not pharmacologically-distinct. In Phase 3 studies, MDMA-AP participants had 3.5 times greater odds of experiencing any TEAE compared with placebo participants. They also had increased odds of muscle tightness, decreased appetite, nausea, excessive perspiration, feeling cold, restlessness, dilated pupils, jaw clenching, uncontrolled eye movements, feeling jittery, non-cardiac chest pain/discomfort, blurred vision, and chills. The higher number of adverse events reaching significance in Phase 3 studies was likely due to increased statistical power, given the larger sample size (N = 194). These results are largely consistent with evidence about the acute and residual effects of MDMA in healthy subjects, suggesting that the side effects of MDMA-AP are primarily due to direct effects of MDMA (or that side effects arising from the combination of MDMA and psychotherapy are not well detected using the methods employed). No differences between MDMA-AP and control groups were observed in the odds of experiencing AESIs related to suicide risk or cardiac function, however, these are likely rare adverse events that were unlikely to reach significance in the meta-analysis. Nonetheless, AESIs related to suicidality were reported at rates which were similar or lower in the MDMA group compared with control. Regardless of assignment, incidences of suicidality should be an important safety consideration in MDMA-AP trials, as there may be specific risks for people randomized to placebo, given the possibility of high expectations driven by hype about psychedelics coupled with blinding failure. While all RCTs included aimed to examine MDMA-AP's safety, none had adequate adherence to the CONSORT Harms 2022 recommendations for reporting of safety data. Reporting rates for adverse events were also low: 56% of non-serious and 31% of serious adverse events recorded on ClinicalTrial.gov registers were not reported in published articles. The discrepancy in non-serious adverse events was primarily driven by the two Phase 3 studies, which only reported adverse events with at least a two-fold difference between the MDMA-AP and placebo-AP groups. In addition, two studiesstated that there were 'no drugrelated serious adverse events', but otherwise did not systematically report on adverse events. Among the four serious adverse events not reported in these papers, there was one instance of syncope and one of suicidal behavior in the MDMA-AP groups. Greater transparency is required regarding the timing of these events (i.e., did they occur during or immediately after medication sessions?) and the rationale for deeming them unrelated to condition. This review identified several limitations of existing MDMA-AP evidence. First, although most studies reported side effect information, reporting practices were largely insufficient. This finding is not limited to MDMA-AP research (e.g., see) and is consistent with concerns about safety reporting in trials of mental health interventions more broadly. Indeed, evidence from clinical trials outside of psychiatry also suggest that compliance with the guidelines on reporting of harms is often inadequate (e.g.,). Greater emphasis on the CONSORT Harms 2022 recommendations during review is recommended to improve reporting of side effect information. Heterogeneous reporting practices across studies also placed limitations on our ability to combine side effect data for meta-analyses. Most prominently, we had to analyze data from Phase 2 and Phase 3 studies separately due to differences in assessment and reporting of side effects. Further, we could only draw conclusions regarding acute and short-term side effects because insufficient data were available regarding longer-term risks beyond active treatment. Second, certainty of the evidence was rated as very low for Phase 2 side effect outcomes, and low to moderate for Phase 3. The improvement in certainty of the evidence in Phase 3 studies was mainly attributable to their larger more ethno-racially diverse samples. The overall evidence on MDMA-AP, however, consists of a relatively limited number of studies with highly selective samples (i.e., most people volunteering for these studies were excluded from participation). While appropriate for this early stage of research, this means we cannot yet with high confidence determine the safety profile or risk-benefit ratio of MDMA-AP. It is likely that implementation beyond controlled clinical trialsin people with more complex needs-will increase the incidence of side effects. In addition, while heterogeneity was low, in many cases estimates lacked precision. We also could not formally test for publication bias, due to the low number of studies available (<10), however possible sources of publication bias were identified, including the body of evidence largely consisting of small studies sponsored by a single advocacy group. Taken together, there is a need for further independent clinical trials, with larger more representative samples to enable more definitive conclusions about the safety of MDMA-AP. Third, consistent with a previous review, we found that most studies relied on passive monitoring of spontaneously reported side effects. While spontaneous reporting avoids the problem of suggestive questions influencing outcomes, evidence suggests that it likely underestimates the extent of side effects compared with a more systematic approach. One implication is that alongside spontaneous reporting, studies of MDMA-AP should also use systematic checklists or scales to assess expected and general side effects which appear acutely, between doses, and at long-term follow-up. This is particularly important at this early stage of research as the data build about the risk-benefit profile of MDMA-AP. Fourth, given differences in dosage, sample sizes, and reporting procedures between Phase 2 and 3 studies, we were unable to assess whether side effects differed as a function of trial design e.g., for instance due to nocebo effects in placebo-controlled studies. Future trials using comparative effectiveness designs could provide further information about the extent to which expectations contribute to the effects (therapeutic or adverse) of MDMA-AP versus control conditions (e.g., see). Lastly, only four studies assessed the dose-dependent nature of side effects. It is critical for future studies to examine at what dose each side effect emerges to identify the ideal dosage and reduce unnecessary risks.
The evidence synthesized indicates that relative to placebo-AP, MDMA-AP is associated with greater likelihood of experiencing mild to moderate, but largely transient side effects. Findings, however, need to be interpreted cautiously due to limitations of the existing evidence. Our review revealed a need to improve practices for assessing side effects and adherence to reporting guidelines for harms in MDMA-AP studies. Based on results reported to date, any assessment of the risk-benefit profile of MDMA-AP remains limited due to the identified issues. Further large-scale trials which systematically assess side effects (including long-term follow up), comprehensively report all potential sideeffects and follow CONSORT Harms guidelines are recommended. In Australia, and other countries soon expected to implement MDMA-AP, systematic, independent post-marketing studies of real-world side effects are also needed.
Create a free account to open full-text PDFs.
Siegel, A. N., Lipsitz, O., Gill, H. et al. · Journal of Psychiatric Research (2021)
Vizeli, P., Liechti, M. E. · Journal of Psychopharmacology (2017)
Breeksema, J. J., Kuin, B. W., Kamphuis, J. et al. · Journal of Psychopharmacology (2022)
Bahji, A., Forsyth, A., Groll, D. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020)
Varker, T., Watson, L., Gibson, K. et al. · Journal of Psychoactive Drugs (2020)
Illingworth, B. J. G., Lewis, D. J., Lambarth, A. T. et al. · Journal of Psychopharmacology (2020)
Mithoefer, M. C., Feduccia, A. A., Jerome, L. et al. · Psychopharmacology (2019)
Taillefer De Laportalière, T., Jullien, A., Yrondi, A. et al. · Psychological Medicine (2023)
Jardim, A. V., Jardim, D. V., Chaves, B. D. R. et al. · brazilian Journal of Psychiatry (2021)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2010)
Monson, C. M., Wagner, A. C., Mithoefer, A. T. et al. · European Journal of Psychotraumatology (2020)
Oehen, P., Traber, R., Widmer, V. et al. · Journal of Psychopharmacology (2012)
Oehen, P., Gasser, P. · Frontiers in Psychiatry (2022)
Bouso, J. C., Doblin, R., Farré, M. et al. · Journal of Psychoactive Drugs (2008)
Jerome, L., Feduccia, A. A., Wang, J. B. et al. · Psychopharmacology (2020)
Papers in Blossom that reference this study
Ramaekers, J. G., Kuypers, K. P. C., Vollenweider, F. X. · Molecular Psychiatry (2026)
Jacobs, E., Zahid, Z., Hinkle, J. et al. · BMJ (2026)